British Airways denies family boarding on flight to UK after baby's bug bites spark concern
A family flying from Shanghai to London said they were refused boarding onto a British Airways flight after gate staff became concerned over insect bite marks on their baby.
Jonathan Arthur, 34 and his wife Xun Sun, 35, were flying from the Chinese city to London Heathrow for a family wedding when they encountered issues at the gate.
The couple had noticed insect bites on one-year-old Joseph while they were at the gate ready to board, so they asked British Airways staff at Shanghai Pudong Airport where they could buy some allergy medication just in case.
This prompted a check-in desk assistant to call a specialist medical service hotline, who said they could not board due to fears that the rash around the bites was a reaction to Joseph's mild peanut allergy.
The staff were worried that if this was the case, it could worsen during the flight.
British Airways staff then told the couple that they would need a 'fit to fly' letter from a doctor, and they were escorted away from the boarding gate.
The bites disappeared within 10-15 minutes of applying bite cream at the instruction of airport medical staff.
The airport's in-person medical team said that if the bites went down, they would be fine to fly, but the British Airways medical advisor overruled this by asking for a clearance letter, the family claims.
Despite paying £3,000 for their British Airways seats, the family ended up waiting an entire day at the airport after rebooking flights on another airline, which did not require a medical clearance letter.
A British Airways spokesperson told The Independent: 'We take the safety and well-being of our customers very seriously and do everything we can to support them when issues like this arise.
'This includes accessing specialist medical advice to assess an individual's suitability to travel, which is what happened in this case.
'Whilst we appreciate our customer was disappointed with this decision, we never compromise passenger safety.'
British Airways states on its website that you need medical clearance before you can fly if you have had a recent illness, hospitalisation, injury or surgery, have an existing unstable medical condition, need additional oxygen or are travelling for medical reasons.
In the airline's Conditions of Carriage, it also states it can refuse to board you 'if your mental or physical state or health is considered a danger or risk to you, the aircraft or any person in it.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
6 hours ago
- Reuters
Focus: China pharma projects disrupted by Sino-US tensions
SHANGHAI, June 18 (Reuters) - Drug research and development firms in China including WuXi AppTec ( opens new tab and WuXi Biologics ( opens new tab are changing project plans, stockpiling supplies and discussing testing locally, said sources with knowledge of the matter, as they seek to mitigate the impact of U.S.-China trade tensions. China's sprawling pharmaceutical research and manufacturing sector serves global drug giants such as Pfizer (PFE.N), opens new tab and AstraZeneca (AZN.L), opens new tab with a low-cost development model that often uses imported clinical samples, equipment, chemicals and other materials to conduct work. Fears of delay in access to U.S. supply chains and raised import tariffs are spurring biotech and pharmaceutical companies to avoid, pause or consider delaying the start of projects, according to three sources. They are also discussing testing U.S. clinical samples in the U.S., instead of sending them to China for further research, a move that could increase costs, and requesting additional supplies for backup, three other sources said. The six sources who spoke to Reuters are director or executive-level employees involved in various aspects of the industry in China including research and development, manufacturing and supply chains. All but two agreed to speak only on condition of anonymity because of concerns about effects on fundraising plans or they were not authorised to speak to media. The developments have not been reported previously. U.S. and Chinese officials said last week they had agreed on a framework to put a May trade truce back on track and remove China's export restrictions on rare earths, but offered little sign of a durable resolution to longstanding trade differences that have affected products ranging from semiconductors and jet engines to medical equipment and pharmaceuticals. "What kind of long-term policy it could be, you know, what kind of tariff would it be in half a year, in one year... nobody knows. And that's the problem. That's what makes everybody worry and nervous," said Chen Gong, co-founder of NeuExcell Therapeutics, a biotech with its main operations in Suzhou. He said the U.S.-China trade tensions had made him more cautious about investing in a clinical trial and the company would delay its start if it did not have sufficient funding. Reliance on U.S. imports has come into particular focus as trade tensions escalate. In 2024, the U.S. exported diagnostic and laboratory reagents to China valued at about $1.4 billion and prepared culture media for the development or maintenance of microorganisms worth about $125 million, U.N. Comtrade data showed. In a sign of the importance of some of the imports and the damaging effect disruption could have on China's healthcare industry, some U.S.-made goods including diagnostic reagents from Germany's Siemens Healthineers ( opens new tab were exempted from raised Chinese tariffs, that company said in May. China raised its tariffs on U.S. imports to as much as 125% though it has since reduced that to 10% while it works out a more permanent trade deal. WuXi AppTec and a Chinese biotechnology firm that was its research client agreed in May to switch U.S.-made reagents they had been using for a Hepatitis B virus pre-clinical research project into non-U.S. versions due partly to concerns about higher costs from tariffs, a source at the client company said. The project had been temporarily paused during the discussions, which began prior to May, the source said. WuXi AppTec said it makes "every effort to avoid disruptions or delays in the delivery of services to customers." Since April, at least 17 Chinese biotech and pharmaceutical clients have contacted Chinese cell culture media manufacturer JS Biosciences asking it to keep locally-made backup raw materials for production because they were concerned about cost increases or the inability to access foreign supplies, the firm's CEO Luo Shun said. "If they have a product made by us, and we rely on the foreign raw material supply and that raw material will increase in price or is never going to come, obviously it will impact their manufacturing of those life-saving drugs. So obviously, that's their primary concern," Luo said. Another Chinese drug research and development firm decided not to provide a quotation to a foreign pharmaceutical company interested in hiring it for protein drug manufacturing, due to delays in obtaining necessary U.S.-made culture medium from a U.S. subsidiary of Japan's Fujifilm (4901.T), opens new tab, a source at the Chinese firm said. The potential client would likely not have accepted waiting on imports of new supplies into China, which would typically take two to four months, the source said. A Fujifilm Holdings America Corporation spokesperson said Fujifilm Biosciences, one of its life science business units, has made significant investments to build a robust global manufacturing network so that it could navigate any challenges or disruptions, without elaborating on its supply issue involving China. After China announced a large rise in tariffs for U.S. imports in April, WuXi Biologics ( opens new tab placed a bigger-than-normal order for reagents made in the U.S. with a supplier because it was not sure how long that policy action would continue, said a source at the supplier. WuXi Biologics did not respond to requests for comment. Concerns about the potential for U.S. export restrictions led China's Innovent Biologics ( opens new tab and multinational BeOne Medicines ( opens new tab to discuss with Massachusetts-headquartered Thermo Fisher Scientific (TMO.N), opens new tab the prospect of not sending U.S. clinical samples to China, said a source at the U.S. company. Testing U.S. samples in-country instead of in China would be more expensive, the source said. A spokesperson for BeOne said it does not comment on rumours or speculation. Thermo Fisher and Innovent declined to comment.
Daily Mail
8 hours ago
- Daily Mail
Top investors in GP surgery firm Assura oppose £1.7bn bid from US private equity giant KKR
Assura's major shareholders have opposed a tie-up with a US private equity giant. Top ten investors Quilter Cheviot and Schroders, which own around 6 per cent and 5 per cent of shares in the NHS landlord respectively, favour a deal with London-listed rival Primary Health Properties (PHP) over US buyout giant KKR. Allianz, Gravis, Baillie Gifford and Columbia Threadneedle have also leant their support to PHP's bid. Shareholders argued that KKR's proposal undervalues Assura, which owns GP surgeries, hospitals and hospices across the UK. A deal with KKR and its partner Stonepeak would see buildings leased to the NHS fall into the hands of overseas owners. But a takeover by PHP would retain the properties under the ownership of a London-listed business. Assura this week said it would weigh up an improved bid from PHP, despite having backed KKR's £1.7billion offer last week. Marcus Phayre-Mudge, manager of Columbia Threadneedle's TR Property Investment Trust, said: 'The KKR bid simply doesn't offer a premium significant enough to justify walking away from this long-term opportunity. 'That's why we strongly support the PHP-Assura merger and encourage other shareholders to do the same.' A Gravis fund manager said PHP's offer was a 'superior choice for long-term investors'. The KKR bid 'risks crystallising value at what may be a cyclical low', they added. Baillie Gifford investment manager Jon Stewart said the KKR deal was not 'in shareholders' best interests' and 'undervalues Assura's long-term growth potential'. KKR's 'best and final' bid values the company at 52.1p per share, although that includes already declared dividends. Without those, the offer is worth 50.42p, analysts said. Most recently, PHP offered £1.68billion to buy Assura but argued last week that its cash and stock bid is worth more as the value is based on share prices. Assura shares slid 0.1 per cent, or 0.05p, to 50.1p. City exodus goes on Direct Line and Ashtead have moved a step closer to joining the exodus from the London stock market. The £3.7billion takeover of insurer Direct Line by Aviva is set to complete next month after talks with the competition watchdog. Aviva said it is pressing ahead with plans for a court to sanction the deal on July 1. This would see the insurer swallowed up by its larger rival and leave the market. Equipment rental firm Ashtead said it is on course to switch its main stock market listing to New York in early 2026. In the past month, drug maker Indivior and fintech firm Wise said they would switch their main listing to New York.
The Independent
11 hours ago
- The Independent
This affordable face mist is a must-have during the heatwave
The UK is in the midst of a sweat-inducing heatwave, so it would seem The Inkey List knew what it was doing when launching its new hydro-surge dewy face mist (£11, earlier this month. The brand takes an ingredients-led approach to skincare, with affordable price points and no-nonsense, effective formulas – fragrance-free moisturisers, serums without shimmer and eye creams without unnecessarily flashy applicators. This new release – alongside the brand's first cream cleanser – promises to brighten, hydrate and revitalise. But, the question is: how does it perform in practice? I've had my hands on the hydro-surge mist for more than a month now, testing it every day to get the low-down on the formula's highs and lows. Scroll on for my tried and tested review, plus all the info you'll need to shop (and trust me, in this heat, you'll want to). How I tested I've been using The Inkey List's hydro-surge dewy face mist since the end of April, giving me four weeks to put it through its paces before its 6 June launch. I applied the spray twice daily after cleansing and before my serums and moisturisers. I used a generous amount of the liquid – anywhere between three to six sprays – and waited a few seconds for it to absorb into the skin. I've been using it on both make-up-free days and underneath my day-to-day combination of foundation and bronzer, paying attention to any changes to my usual complexion. I also noted any changes in hydration and the feel of the formula on the skin and also considered value for money. Why you can trust IndyBest reviews Lucy Smith has many years of experience as a beauty writer and has been specifically reviewing products from The Inkey List since 2021 – her most recent write-up on the brand saw her put The Inkey List's tripeptide lip balm to the test. Lucy is well-versed in the skincare realm, having reviewed everything from the best hyaluronic acids to SPF moisturisers and LED face masks.
